Publication | Open Access

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation

Surgical OncologyUrologyGenitourinary CancerSuperficial Bladder CancerMedicineSystemic T-cell ActivationImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentIntracavitary Prophylactic Treatment